- Conditions
- Hepatitis C, Hepatocellular Carcinoma
- Interventions
- Sofosbuvir, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–9
of 9
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pre-Bronchiolitis Obliterans Syndrome
- Interventions
- ARINA-1, Standard of care only
- Drug · Other
- Lead sponsor
- Renovion, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 15 more
- Conditions
- Gestational Hypertension, Preeclampsia, Chronic Hypertension Complicating Pregnancy
- Interventions
- App-based remote blood pressure monitoring, text-message based remote blood pressure monitoring
- Behavioral
- Lead sponsor
- Women and Infants Hospital of Rhode Island
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Providence, Rhode Island
- Conditions
- Sinusitis, Chronic
- Interventions
- Sinus surgery
- Procedure
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Chronic Graft Versus Host Disease
- Interventions
- Belumosudil, Biospecimen Collection, Electronic Health Record Review, Placebo Administration
- Drug · Procedure · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 5
- States / cities
- Duarte, California • Tampa, Florida • Boston, Massachusetts + 2 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- INCA034176, Best available Treatment (BAT)
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Palo Alto, California + 8 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Belumosudil (KD025)
- Drug
- Lead sponsor
- Kadmon, a Sanofi Company
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 159 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2023
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Duarte, California + 30 more
- Conditions
- Chronic Graft-Versus-Host Disease (cGVHD)
- Interventions
- Vimseltinib
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 26
- States / cities
- Duarte, California • Los Angeles, California • Orange, California + 22 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- axatilimab
- Drug
- Lead sponsor
- Syndax Pharmaceuticals
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 11
- States / cities
- Birmingham, Alabama • Duarte, California • Miami, Florida + 8 more